Phosphoinositide 3-kinase-based dual-target inhibitors for cancer therapy: rational design, structure-activity relationships and biological evaluation

Review paper

Authors

  • Jayshree Jangir Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara-391760, Gujarat, India https://orcid.org/0009-0002-4124-9323
  • Prachi Patel Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara-391760, Gujarat, India https://orcid.org/0009-0009-4584-8156
  • Drashti Shah Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara-391760, Gujarat, India https://orcid.org/0000-0002-7495-5366
  • Ashish Shah Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat, India https://orcid.org/0000-0003-0817-5940
  • Vashisth Bhavsar Department of Pharmacology, Dharamsinh Desai University, Nadiad, Gujarat, India https://orcid.org/0000-0002-3845-7941
  • Ashish Patel Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara-391760, Gujarat, India https://orcid.org/0000-0001-5773-3756

DOI:

https://doi.org/10.5599/admet.3693

Keywords:

Phosphoinositide 3-kinase, ADMET, molecular hybridization, structure-activity relationships, structure-based drug design

Abstract

Background and purpose: The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is dysregulated in 30-50 % of human cancers. PI3K inhibition is clinically validated, yet of the seven PI3K pathway inhibitors approved by the US Food and Drug Administration, four have had indications withdrawn and two are no longer marketed, principally because narrow therapeutic windows and overall-survival detriments offset progression-free survival gains. Pathway reactivation and adaptive resistance further limit single-agent activity, motivating single-molecule dual-target inhibitors. Experimental approach: A structured search (January 2019 - July 2026) retained original medicinal-chemistry reports of single chemical entities engaging PI3K with a second oncology target, for which biochemical potency against both targets and an interpretable structure-activity relationship were reported. Five combinations dominated retrieval - PI3K/mTOR, PI3K/HDAC, PI3K/PARP, EGFR/PI3K and PI3K/BRD4 - and twenty representative leads are analysed. Key results: Each compound is assigned an explicit level of evidence for dual-target engagement, distinguishing measured biochemical and cellular target engagement from structural hypotheses generated by docking; nine of twenty leads reach the highest tier. In vivo pharmacokinetics are available for only seven leads and plasma protein binding for none, so a uniform in silico ADMET profile is reported for all compounds. Predictions reproduced the solubility-permeability trade-off and indicated near-complete plasma protein binding for the most lipophilic hybrids, but under-predicted clearance by up to two orders of magnitude and returned false-positive hERG calls for every compound in which the liability was measured. Solubilizing groups on the solvent-exposed vector improved solubility more than 100-fold without loss of dual potency, whereas carboxylic acids, hydroxamate zinc-binding groups and N-acylhydrazone linkers each improved one property at a cost in potency, permeability, oral bioavailability or chemical stability. Conclusion: Dual-target PI3K inhibition is now clinically validated: the pan-PI3K/mTORC1/2 inhibitor gedatolisib was approved in July 2026. The principal obstacles are not biochemical potency, which is routinely sub-nanomolar, but the 80- to 340-fold potency imbalance between the two targets of most hybrids, the lack of experimental DMPK data, low oral bioavailability of benzamide-based hybrids, and a regulatory environment now requiring randomized evidence of survival benefit.

Downloads

Download data is not yet available.

References

[1] F. Bray, M. Laversanne, H. Sung, J. Ferlay, R. L. Siegel, I. Soerjomataram, A. Jemal. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer Journal for Clinicians 74 (2024) 229-263. https://doi.org/10.3322/caac.21834 DOI: https://doi.org/10.3322/caac.21834

[2] D. Hanahan. Hallmarks of Cancer: New Dimensions. Cancer Discovery 12 (2022) 31-46. https://doi.org/10.1158/2159-8290.CD-21-1059 DOI: https://doi.org/10.1158/2159-8290.CD-21-1059

[3] M. Brindisi, S. M. Kessler, V. Kumar, C. Zwergel. Multi-Target Directed Ligands for the Treatment of Cancer. Frontiers in Oncology 12 (2022) 980141. https://doi.org/10.3389/fonc.2022.980141 DOI: https://doi.org/10.3389/fonc.2022.980141

[4] A. Zięba, P. Stępnicki, D. Matosiuk, A. Kaczor. What Are the Challenges with Multi-Targeted Drug Design for Complex Diseases? Expert Opinion on Drug Discovery 17 (2022) 673-683. https://doi.org/10.1080/17460441.2022.2072827 DOI: https://doi.org/10.1080/17460441.2022.2072827

[5] P. Garg, J. Malhotra, P. Kulkarni, D. Horne, R. Salgia, S. Singhal. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers 16 (2024) 2478. https://doi.org/10.3390/cancers16132478 DOI: https://doi.org/10.3390/cancers16132478

[6] L. Shen, B. Wang, S.-P. Wang, S.-K. Ji, M.-J. Fu, S.-W. Wang, W.-Q. Hou, X.-J. Dai, H.-M. Liu. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy. Journal of Medicinal Chemistry 67 (2024) 922-951. https://doi.org/10.1021/acs.jmedchem.3c02133 DOI: https://doi.org/10.1021/acs.jmedchem.3c02133

[7] L. Chen, X.-M. Chen, Z.-C. Mao, Y. Gou, X.-L. Ma, J.-H. Wei, R.-Z. Huang, Y. Zhang. Discovery of Diaryl Piperidone-Sulfonamide as a Novel Dual-Target Inhibitor of STAT3/CAIX Inducing Ferroptosis in Triple-Negative Breast Cancer Cells. Journal of Medicinal Chemistry 68 (2025) 12493-12512. https://doi.org/10.1021/acs.jmedchem.5c00126 DOI: https://doi.org/10.1021/acs.jmedchem.5c00126

[8] J. Zhang, P. He, W. Wang, Y. Wang, H. Yang, Z. Hu, Y. Song, J. Chang, B. Yu. Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers. Journal of Medicinal Chemistry 68 (2025) 5954-5972. https://doi.org/10.1021/acs.jmedchem.5c00267 DOI: https://doi.org/10.1021/acs.jmedchem.5c00267

[9] T. O. Omolekan, J. C. Chamcheu, C. Buerger, S. Huang. PI3K/AKT/mTOR Signaling Network in Human Health and Diseases. Cells 13 (2024) 1500. https://doi.org/10.3390/cells13171500 DOI: https://doi.org/10.3390/cells13171500

[10] K. S. Shan, A. Bonano-Rios, N. W. Y. Theik. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers. International Journal of Molecular Sciences 25 (2024) 1973. https://doi.org/10.3390/ijms25041973 DOI: https://doi.org/10.3390/ijms25041973

[11] W. Wiese, J. Barczuk, O. Racinska, N. Siwecka, W. Rozpedek-Kaminska, A. Slupianek, R. Sierpinski, I. Majsterek. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies--New Therapeutic Possibilities. Cancers 15 (2023) 5297. https://doi.org/10.3390/cancers15215297 DOI: https://doi.org/10.3390/cancers15215297

[12] D. Hassan, C. W. Menges, J. R. Testa, A. Bellacosa. AKT Kinases as Therapeutic Targets. Journal of Experimental and Clinical Cancer Research 43 (2024) 313. https://doi.org/10.1186/s13046-024-03207-4 DOI: https://doi.org/10.1186/s13046-024-03207-4

[13] E. Tortorella, S. Giantulli, A. Sciarra, I. Silvestri. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways. International Journal of Molecular Sciences 24 (2023) 2046. https://doi.org/10.3390/ijms24032046 DOI: https://doi.org/10.3390/ijms24032046

[14] B. A. F. dos S. Trigueiros, I. J. S. Santos, F. P. Pimenta, A. R. A. Ávila. Long Way to Go: A Scenario for Clinical Trials of PI3K Inhibitors in Treating Cancer. Cancer Control 31 (2024). https://doi.org/10.1177/10732748241238047 DOI: https://doi.org/10.1177/10732748241238047

[15] Y. Liu, Q. Sun, X. Wei. Strategies and Techniques for Preclinical Therapeutic Targeting of PI3K in Oncology: Where Do We Stand in 2024? Expert Opinion on Therapeutic Targets 28 (2024) 221-232. https://doi.org/10.1080/14728222.2024.2342522 DOI: https://doi.org/10.1080/14728222.2024.2342522

[16] X. Liu, Y. Chen, W. Han, Y. Chen, W. Feng, Q. Zhou, M.-W. Wang. Structural Insights into the Development of Inhibitors against Cancer-Specific Mutations of PI3Kα. Annual Review of Pharmacology and Toxicology 66 (2026) 465-485. https://doi.org/10.1146/annurev-pharmtox-082924-022724 DOI: https://doi.org/10.1146/annurev-pharmtox-082924-022724

[17] D. A. Sabbah, R. Hajjo, S. K. Bardaweel, H. A. Zhong. Targeting the PI3K/AKT Signaling Pathway in Anticancer Research: A Recent Update on Inhibitor Design and Clinical Trials (2020-2023). Expert Opinion on Therapeutic Patents 34 (2024) 141-158. https://doi.org/10.1080/13543776.2024.2338100 DOI: https://doi.org/10.1080/13543776.2024.2338100

[18] H. Zhong, Z. Zhou, H. Wang, R. Wang, K. Shen, R. Huang, Z. Wang. The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review. International Journal of Molecular Sciences 25 (2024) 13376. https://doi.org/10.3390/ijms252413376 DOI: https://doi.org/10.3390/ijms252413376

[19] I. M. Browne, A. F. C. Okines. Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer. Cancers 16 (2024) 2259. https://doi.org/10.3390/cancers16122259 DOI: https://doi.org/10.3390/cancers16122259

[20] H. Qi, J. Wen, H. A. Xu. Patent Review of Mutant-Selective PI3Kα Inhibitors for the Treatment of Different Cancers (2021-2025). Expert Opinion on Therapeutic Patents (2026) 865-891. https://doi.org/10.1080/13543776.2026.2704853 DOI: https://doi.org/10.1080/13543776.2026.2704853

[21] Y. B. Cho, K. S. Park. The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions. Medicina 61 (2025) 518. https://doi.org/10.3390/medicina61030518 DOI: https://doi.org/10.3390/medicina61030518

[22] S. Peng, Q. Zhang, H. Tian, J. Zhang, J. Deng, H. Qi, D. Wu, T. Du, K. Zhang, J. Ge, L. Sheng, S. Lin, M. Ji, H. Xu. Discovery and Optimization of Potent PROTAC Degraders of Phosphoinositide 3-Kinase with Significant In vivo Anticancer Efficacy. Journal of Medicinal Chemistry 68 (2025) 12800-12818. https://doi.org/10.1021/acs.jmedchem.5c00679 DOI: https://doi.org/10.1021/acs.jmedchem.5c00679

[23] K. Cerma, F. Piacentini, L. Moscetti, M. Barbolini, A. Fabi. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. Biomedicines 11 (2023) 109. https://doi.org/10.3390/biomedicines11010109 DOI: https://doi.org/10.3390/biomedicines11010109

[24] D. Meng, W. He, Y. Zhang, Z. Liang, J. Zheng, X. Zhang, X. Zheng, P. Zhan, H. Chen, W. Li, L. Cai. Development of PI3K Inhibitors: Advances in Clinical Trials and New Strategies. Pharmacological Research 173 (2021) 105900. https://doi.org/10.1016/j.phrs.2021.105900 DOI: https://doi.org/10.1016/j.phrs.2021.105900

[25] L. Liu, S. L. Graff, Y. Wang. New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer--Current State and Future Directions. Cancers 17 (2025) 16. https://doi.org/10.3390/cancers17010016 DOI: https://doi.org/10.3390/cancers17010016

[26] N. C. Turner, S.-A. Im, C. Saura, D. Juric, S. Loibl, K. Kalinsky, P. Schmid, S. Loi, P. Sunpaweravong, A. Musolino, H. Li, Q. Zhang, Z. Nowecki, R. Leung, E. Thanopoulou, N. Shankar, G. Lei, T. J. Stout, K. E. Hutchinson, J. L. Schutzman, C. Song, K. L. Jhaveri. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. The New England Journal of Medicine 391 (2024) 1584-1596. https://doi.org/10.1056/NEJMoa2404625 DOI: https://doi.org/10.1056/NEJMoa2404625

[27] X. Lin, Y. Zhang, H. Huang, W. Zhuang, L. Wu. Post-Marketing Safety Concern of PI3K Inhibitors in the Cancer Therapies: An 8-Year Disproportionality Analysis from the FDA Adverse Event Reporting System. Expert Opinion on Drug Safety 24 (2025) 925-936. https://doi.org/10.1080/14740338.2024.2387317 DOI: https://doi.org/10.1080/14740338.2024.2387317

[28] T. Banerjee, M. S. Kim, A. Haslam, V. Prasad. Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. JAMA Internal Medicine 183 (2023) 435-441. https://doi.org/10.1001/jamainternmed.2023.0190 DOI: https://doi.org/10.1001/jamainternmed.2023.0190

[29] Y. Zhang, Z. Ma, Y. Wang, X. Feng, Z. An. Phosphatidylinositol 3-Kinase Inhibitor-Related Pneumonitis: A Systematic Review and Meta-Analysis. Expert Review of Clinical Pharmacology 16 (2023) 855-863. https://doi.org/10.1080/17512433.2023.2238602 DOI: https://doi.org/10.1080/17512433.2023.2238602

[30] M. S. Davids, O. A. O'Connor, W. Jurczak, F. Samaniego, T. S. Fenske, P. L. Zinzani, M. R. Patel, N. Ghosh, B. D. Cheson, E. Derenzini, D. M. Brander, J. A. Reeves, W. Knopińska-Posłuszny, J. N. Allan, T. Phillips, P. F. Caimi, E. Lech-Maranda, J. M. Burke, R. Agajanian, R. Pettengell, L. A. Leslie, C. Y. Cheah, G. Fonseca, J. Essell, J. C. Chavez, J. M. Pagel, J. P. Sharman, Y. Hsu, H. P. Miskin, P. Sportelli, M. S. Weiss, I. W Flinn. Integrated Safety Analysis of Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor, in Relapsed/Refractory Lymphoid Malignancies. Blood Advances 5 (2021) 5332-5343. https://doi.org/10.1182/bloodadvances.2021005132 DOI: https://doi.org/10.1182/bloodadvances.2021005132

[31] M. Dreyling, A. Santoro, L. Mollica, S. Leppä, G. A. Follows, G. Lenz, W. S. Kim, A. Nagler, P. Panayiotidis, J. Demeter, M. Özcan, M. Kosinova, K. Bouabdallah, F. Morschhauser, D. A. Stevens, D. Trevarthen, M. Giurescu, L. Cupit, L. Liu, K. Köchert, H. Seidel, C. Peña, S. Yin, F. Hiemeyer, J. Garcia-Vargas, B. H. Childs, P. L Zinzani. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology 35 (2017) 3898-3905. https://doi.org/10.1200/JCO.2017.75.4648 DOI: https://doi.org/10.1200/JCO.2017.75.4648

[32] V. Asati, A. Anant, D. K. Mahapatra, S. K. Bharti. Recent Advances in PI3 Kinase Inhibitors: Anticancer Activities and Structure-Activity Relationships. Mini-Reviews in Medicinal Chemistry 22 (2022) 2146-2165. https://doi.org/10.2174/1389450123666220202154757 DOI: https://doi.org/10.2174/1389450123666220202154757

[33] K. R. Ibáñez, T. T. Huang, J. M. Lee. Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers. Cells 13 (2024) 1064. https://doi.org/10.3390/cells13121064 DOI: https://doi.org/10.3390/cells13121064

[34] X. Li, H. Wang, S. Lin, T. Chen. Efficacy and Safety of PI3K Inhibitors Combined with Fulvestrant for HR+/HER2− Advanced Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology 15 (2025) 1556978. https://doi.org/10.3389/fonc.2025.1556978 DOI: https://doi.org/10.3389/fonc.2025.1556978

[35] A. D. S. Lima, L. M. Lima. Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates. Pharmaceuticals 19 (2026) 130. https://doi.org/10.3390/ph19010130 DOI: https://doi.org/10.3390/ph19010130

[36] B. Zhang, P.-C. Leung, W. C.-S. Cho, C.-K. Wong, D. Wang. Targeting PI3K Signaling in Lung Cancer: Advances, Challenges and Therapeutic Opportunities. Journal of Translational Medicine 23 (2025) 184. https://doi.org/10.1186/s12967-025-06144-8 DOI: https://doi.org/10.1186/s12967-025-06144-8

[37] S. E. Conduit, N. Vasan, J. R. Brown, M. W. D. Perry, B. A. Vanhaesebroeck. Renaissance in Targeting the PI3K/AKT/mTOR Pathway. Nature Reviews Drug Discovery 25 (2026) 469-493. https://doi.org/10.1038/s41573-026-01388-5 DOI: https://doi.org/10.1038/s41573-026-01388-5

[38] A. Hassan, C. Aubel. The PI3K/Akt/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies. Cancers 17 (2025) 2232. https://doi.org/10.3390/cancers17132232 DOI: https://doi.org/10.3390/cancers17132232

[39] P. Yudaev, Y. Aleksandrova, M. Neganova. Current Research in Polypharmacology for Cancer Treatment Using Dual-Target Histone Deacetylase Inhibitors. International Journal of Molecular Sciences 27 (2026) 6604. https://doi.org/10.3390/ijms27156604 DOI: https://doi.org/10.3390/ijms27156604

[40] I. M. Browne, F. André, S. Chandarlapaty, L. A. Carey, N. C. Turner. Optimal Targeting of PI3K-AKT and mTOR in Advanced Oestrogen Receptor-Positive Breast Cancer. The Lancet Oncology 25 (2024) e139-e151. https://doi.org/10.1016/S1470-2045(23)00676-9 DOI: https://doi.org/10.1016/S1470-2045(23)00676-9

[41] S. Oljacic, M. Popovic-Nikolic, B. Filipic, Z. Gagic, K. Nikolic. Computer-aided Drug Discovery of Epigenetic Modulators in Dual-target Therapy of Multifactorial Diseases. Current Topics in Medicinal Chemistry 25 (2025) 1907-1939. https://doi.org/10.2174/0115680266337668241025061804 DOI: https://doi.org/10.2174/0115680266337668241025061804

[42] M. Qiang, Z. Chen, H. Liu, J. Dong, K. Gong, X. Zhang, P. Huo, J. Zhu, Y. Shao, J. Ma, B. Zhang, W. Liu, M. Tang. Targeting the PI3K/AKT/mTOR Pathway in Lung Cancer: Mechanisms and Therapeutic Targeting. Frontiers in Pharmacology 16 (2025) 1516583. https://doi.org/10.3389/fphar.2025.1516583 DOI: https://doi.org/10.3389/fphar.2025.1591443

[43] S. Sen, D. Karati. Advanced Cancer Therapy: Unlocking the Potential of Small Molecule Inhibitors. Future Medicinal Chemistry 17 (2025) 2627-2655. https://doi.org/10.1080/17568919.2025.2571021 DOI: https://doi.org/10.1080/17568919.2025.2571021

[44] X. Li, X. Li, F. Liu, S. Li, D. Shi. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. Journal of Medicinal Chemistry 64 (2021) 10581-10605. https://doi.org/10.1021/acs.jmedchem.1c00683 DOI: https://doi.org/10.1021/acs.jmedchem.1c00683

[45] A. Mishra, A. Thakur, R. Sharma, R. Onuku, C. Kaur, J. P. Liou, S.-P. Hsu, K. Nepali. Scaffold Hopping Approaches for Dual-Target Antitumor Drug Discovery: Opportunities and Challenges. Expert Opinion on Drug Discovery 19 (2024) 1355-1381. https://doi.org/10.1080/17460441.2024.2409674 DOI: https://doi.org/10.1080/17460441.2024.2409674

[46] O. Al Jarroudi, H. Chibani, S. A. Brahmi, S. Afqir. Inhibition of the PI3K/AKT/mTOR Pathway in Pancreatic Cancer: Is It a Worthwhile Endeavor? Therapeutic Advances in Medical Oncology 16 (2024) 17588359241284911. https://doi.org/10.1177/17588359241284911 DOI: https://doi.org/10.1177/17588359241284911

[47] L. Lei, M. Canning, E. Sakach, A. Lateef, L. Kamga, M. Abid, K. Kalinsky, S. Gandhi. Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2− Advanced Breast Cancer. Drugs (2026). https://doi.org/10.1007/s40265-026-02347-5 DOI: https://doi.org/10.1007/s40265-026-02347-5

[48] T. Al Anta, O. Al Shehadat, J. Taneera, S. M. Aleidi, A. A. Abuhelwa, K. H. Alzoubi, M. H. Semreen, W. El-Huneidi, E. Abu-Gharbieh, Y. Bustanji. Dual Inhibition of PI3K and mTOR in Cancer Therapy: Mechanisms, Clinical Potential, and Future Perspectives. Pharmacy Practice 24 (2026) 1-13. https://doi.org/10.18549/PharmPract.2026.1.3337 DOI: https://doi.org/10.18549/PharmPract.2026.1.3337

[49] J. Zhan, M. Jücker. The Role of PI3K/AKT/mTOR Signaling in Tumor Radioresistance and Advances in Inhibitor Research. International Journal of Molecular Sciences 26 (2025) 6853. https://doi.org/10.3390/ijms26146853 DOI: https://doi.org/10.3390/ijms26146853

[50] M. Shenoy, E. Rathi, K. S. Udupa, S. K. Prasada, K. S. R. Pai, S. G. Kini. Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are We on the Right Track? Current Medicinal Chemistry 32 (2025) 1121-1143. https://doi.org/10.2174/0109298673293028240326051835 DOI: https://doi.org/10.2174/0109298673293028240326051835

[51] X. Wu, Y. Xu, Q. Liang, X. Yang, J. Huang, J. Wang, H. Zhang, J. Shi. Recent Advances in Dual PI3K/mTOR Inhibitors for Tumor Treatment. Frontiers in Pharmacology 13 (2022) 875372. https://doi.org/10.3389/fphar.2022.875372 DOI: https://doi.org/10.3389/fphar.2022.875372

[52] J. Hu, S. Fu, Z. Zhan, J. Zhang. Advancements in Dual-Target Inhibitors of PI3K for Tumor Therapy: Clinical Progress, Development Strategies, Prospects. European Journal of Medicinal Chemistry 265 (2024) 116109. https://doi.org/10.1016/j.ejmech.2023.116109 DOI: https://doi.org/10.1016/j.ejmech.2023.116109

[53] Y. Yu, Y. Han, F. Zhang, Z. Gao, T. Zhu, S. Dong, M. Ma. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. Journal of Medicinal Chemistry 63 (2020) 3028-3046. https://doi.org/10.1021/acs.jmedchem.9b01736 DOI: https://doi.org/10.1021/acs.jmedchem.9b01736

[54] T.-T. Wu, Q.-Q. Guo, Z.-L. Chen, L.-L. Wang, Y. Du, R. Chen, Y.-H. Mao, S.-G. Yang, J. Huang, J.-T. Wang, L. Wang, L. Tang, J.-Q. Zhang. Design, Synthesis and Bioevaluation of Novel Substituted Triazines as Potential Dual PI3K/mTOR Inhibitors. European Journal of Medicinal Chemistry 203 (2020) 112637. https://doi.org/10.1016/j.ejmech.2020.112637 DOI: https://doi.org/10.1016/j.ejmech.2020.112637

[55] C. Li, Y. Han, Z. Wang, Y. Yu, C. Wang, Z. Ren, Y. Guo, T. Zhu, X. Li, S. Dong, M. Ma. Function-Oriented Synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine Derivatives as Potent PI3K/mTOR Dual Inhibitors. European Journal of Medicinal Chemistry 247 (2023) 115030. https://doi.org/10.1016/j.ejmech.2022.115030 DOI: https://doi.org/10.1016/j.ejmech.2022.115030

[56] Y. Yang, X. Sun, L. Luo, R. Peng, R. Yang, Z. Cheng, Y. Lv, H. Li, Q. Tang, W. Zhu, D. Qiao, S. Xu. Discovery of Novel Potent PI3K/mTOR Dual-Target Inhibitors Based on Scaffold Hopping: Design, Synthesis, and Antiproliferative Activity. Archiv der Pharmazie 356 (2023) 2300403. https://doi.org/10.1002/ardp.202300403 DOI: https://doi.org/10.1002/ardp.202300403

[57] H. Gao, Z. Li, K. Wang, Y. Zhang, T. Wang, F. Wang, Y. Xu. Design, Synthesis, and Biological Evaluation of Sulfonamide Methoxypyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. Pharmaceuticals 16 (2023) 461. https://doi.org/10.3390/ph16030461 DOI: https://doi.org/10.3390/ph16030461

[58] D. Yevale, N. Teraiya, T. Lalwani, M. Dalasaniya, K. Kapadiya, R. K. Ameta, C. B. Sangani, Y.-T. Duan. PI3Kδ and mTOR Dual Inhibitors: Design, Synthesis and Anticancer Evaluation of 3-Substituted Aminomethylquinoline Analogues. Bioorganic Chemistry 147 (2024) 107323. https://doi.org/10.1016/j.bioorg.2024.107323 DOI: https://doi.org/10.1016/j.bioorg.2024.107323

[59] D. Yevale, V. Buha, D. U. Sangani, N. Teraiya, C. B. Sangani, N. Patel. Novel Anticancer Inhibitors Targeting the PI3K/Akt/mTOR Signaling Route and Apoptosis Inducers: A Study on the Apoptosis Mechanism via the Intrinsic Mitochondrial-Mediated Pathway. Chemico-Biological Interactions 419 (2025) 111635. https://doi.org/10.1016/j.cbi.2025.111635 DOI: https://doi.org/10.1016/j.cbi.2025.111635

[60] W. Zhu, J. Chen, W. Zhang, Y. Wang, F. Xu, J. Pang. Discovery of the First Potent PI3K/mTOR Dual-Targeting PROTAC Degrader for Efficient Modulation of the PI3K/AKT/mTOR Pathway. Journal of Medicinal Chemistry 68 (2025) 26188-26205. https://doi.org/10.1021/acs.jmedchem.5c02244 DOI: https://doi.org/10.1021/acs.jmedchem.5c02244

[61] C. A. Silva, R. M. Pillpe-Meza, W. L. Gouveia, J. D. S. Trindade, G. Barbosa, A. M. S. Vieira, H. V. Tolomeu, R. F. Pereira, C. A. N. Santos, L. Freire-de-Lima, L. M. Lima. New Dual Pan-PI3K/mTOR Inhibitor: Design, Synthesis, Cytotoxic Action, Permeation, Metabolic Stability, and In Silico Protein-Ligand Interaction. ACS Omega 11 (2026) 9719-9733. https://doi.org/10.1021/acsomega.5c10162 DOI: https://doi.org/10.1021/acsomega.5c10162

[62] W. Zeng, Z. Zhang, K. Li, Y. Yin, S. Dong, M. Ma. HDAC and PI3K Dual Inhibitors in the Treatment of Cancers: Current Status, Trends, and Solutions. European Journal of Medicinal Chemistry 304 (2026) 118511. https://doi.org/10.1016/j.ejmech.2025.118511 DOI: https://doi.org/10.1016/j.ejmech.2025.118511

[63] Madhukumari, A. Handattu Shankaranarayana, S. P. Nair, S. A. Kumar, D. Bidye, G. V. Pujar. Dual HDAC/PI3K Inhibitors as a Potential and Emerging Cancer Therapy. Future Medicinal Chemistry 18 (2026) 2257-2279. https://doi.org/10.1080/17568919.2026.2699690 DOI: https://doi.org/10.1080/17568919.2026.2699690

[64] Y. Cheng, Y. Zhuang, N. Zhu, Y. Yu, M. Hu. Current Landscape of Hydroxamic Acid Hybrids with Anti-Colorectal Cancer Potential. Archiv der Pharmazie 358 (2025) 70066. https://doi.org/10.1002/ardp.70066 DOI: https://doi.org/10.1002/ardp.70066

[65] L. Hegedüs, S. Qaisieh, C. Stülpnagel, Y. Ganjeh Khor Dezfouli, W. Tambo, F. Doerr, N. Baldes, D. Theegarten, M. Schuler, S. Bölükbas, B. Hegedüs. Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression. Cells 14 (2025) 1599. https://doi.org/10.3390/cells14201599 DOI: https://doi.org/10.3390/cells14201599

[66] S. Dash, S. Shehensha, A. K. Dhar. PI3K/HDAC Dual Inhibitors as Potential Anticancer Therapeutics: An Insight into Design Strategies and Structure Activity Relationships. ChemistrySelect 11 (2026) 73651. https://doi.org/10.1002/slct.73651 DOI: https://doi.org/10.1002/slct.73651

[67] E. Martino, S. Thakur, A. Kumar, A. K. Yadav, D. Boschi, D. Kumar, M. Lolli. Insight in Quinazoline-Based HDAC Inhibitors as Anti-Cancer Agents. Mini-Reviews in Medicinal Chemistry 24 (2024) 1983-2007. https://doi.org/10.2174/0113895575303614240527093106 DOI: https://doi.org/10.2174/0113895575303614240527093106

[68] Z. Liu, Z. Yang. Histone Deacetylase-Based Dual Inhibitors: Research Progress Focusing on Non-Small Cell Lung Cancer Therapy. RSC Medicinal Chemistry 17 (2026) 3168-3179. https://doi.org/10.1039/D6MD00063K DOI: https://doi.org/10.1039/D6MD00063K

[69] D. A. Rodrigues, F. S. Guerra, F. S. Sagrillo, P. S. M. Pinheiro, M. A. Alves, S. Thota, L. S. Chaves, C. M. R. Sant'Anna, P. D. Fernandes, C. A. M. Fraga. Design, Synthesis and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. ChemMedChem 15 (2019) 539-551. https://doi.org/10.1002/cmdc.201900716 DOI: https://doi.org/10.1002/cmdc.201900716

[70] Z.-X. Wang, S. Wang, X.-P. Qiao, W.-B. Li, J.-T. Shi, Y.-R. Wang, S.-W. Chen. Design, Synthesis and Biological Evaluation of Novel Pyrazinone Derivatives as PI3K/HDAC Dual Inhibitors. Bioorganic Medicinal Chemistry 74 (2022) 117067. https://doi.org/10.1016/j.bmc.2022.117067 DOI: https://doi.org/10.1016/j.bmc.2022.117067

[71] J. Deng, B. Hou, X. Hou, Y. Chen, T. Zhang, H. Chen, Y. Wang, X. Li. Discovery of Benzamide-Based PI3K/HDAC Dual Inhibitors with Marked Pro-Apoptosis Activity in Lymphoma Cells. European Journal of Medicinal Chemistry 262 (2023) 115915. https://doi.org/10.1016/j.ejmech.2023.115915 DOI: https://doi.org/10.1016/j.ejmech.2023.115915

[72] K. Zhang, R. Huang, M. Ji, S. Lin, F. Lai, D. Wu, H. Tian, J. Bi, S. Peng, J. Hu, L. Sheng, Y. Li, X. Chen, H. Xu. Rational Design and Optimization of Novel 4-Methyl Quinazoline Derivatives as PI3K/HDAC Dual Inhibitors with Benzamide as Zinc Binding Moiety for the Treatment of Acute Myeloid Leukemia. European Journal of Medicinal Chemistry 264 (2024) 116015. https://doi.org/10.1016/j.ejmech.2023.116015 DOI: https://doi.org/10.1016/j.ejmech.2023.116015

[73] J. Sun, J. Chen, Y. Lou, Z. Chen, X. Jiang, J.-P. Monserrat, Y. Zhang, L. Shen. Design, Synthesis and Bioactive Evaluation of Novel Quinoline-Linked Sulfonamide-Pyridine Derivatives as PI3K/HDAC Dual-Target Inhibitors. European Journal of Medicinal Chemistry 301 (2025) 118170. https://doi.org/10.1016/j.ejmech.2025.118170 DOI: https://doi.org/10.1016/j.ejmech.2025.118170

[74] Z. Lin, L. Wang, Z. Xing, F. Wang, X. Cheng. Update on Combination Strategies of PARP Inhibitors. Cancer Control 31 (2024) 10732748241298329. https://doi.org/10.1177/10732748241298329 DOI: https://doi.org/10.1177/10732748241298329

[75] Y.-H. Soung, J. Chung. Combination Treatment Strategies to Overcome PARP Inhibitor Resistance. Biomolecules 13 (2023) 1480. https://doi.org/10.3390/biom13101480 DOI: https://doi.org/10.3390/biom13101480

[76] K. Shen, L. Yang, F.-Y. Li, F. Zhang, L.-L. Ding, J. Yang, J. Lu, N.-N. Wang, Y. Wang. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer. Current Drug Targets 23 (2022) 145-155. https://doi.org/10.2174/1389450122666210617111304 DOI: https://doi.org/10.2174/1389450122666210617111304

[77] J. Wang, H. Li, G. He, Z. Chu, K. Peng, Y. Ge, Q. Zhu, Y. Xu. Discovery of Novel Dual Poly(ADP-Ribose) Polymerase (PARP) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy. Journal of Medicinal Chemistry 63 (2020) 122-139. https://doi.org/10.1021/acs.jmedchem.9b00622 DOI: https://doi.org/10.1021/acs.jmedchem.9b00622

[78] J. Wang, G. He, H. Li, Y. Ge, S. Wang, Y. Xu, Q. Zhu. Discovery of Novel PARP/PI3K Dual Inhibitors with High Efficiency against BRCA-Proficient Triple Negative Breast Cancer. European Journal of Medicinal Chemistry 213 (2021) 113054. https://doi.org/10.1016/j.ejmech.2020.113054 DOI: https://doi.org/10.1016/j.ejmech.2020.113054

[79] Z. Wu, Y. Bai, J. Jin, T. Jiang, H. Shen, Q. Ju, Q. Zhu, Y. Xu. Discovery of Novel and Potent PARP/PI3K Dual Inhibitors for the Treatment of Cancer. European Journal of Medicinal Chemistry 217 (2021) 113357. https://doi.org/10.1016/j.ejmech.2021.113357 DOI: https://doi.org/10.1016/j.ejmech.2021.113357

[80] T. Wang, Y. Wang, J. Lu, J. Chen, L. Wang, Z. Ouyang, W. Ouyang, C. Hu, J. Weng, J.-Q. Zhang. Design, Synthesis and Bioevaluation of Dual EGFR-PI3Kα Inhibitors for Potential Treatment of NSCLC. Bioorganic Chemistry 151 (2024) 107714. https://doi.org/10.1016/j.bioorg.2024.107714 DOI: https://doi.org/10.1016/j.bioorg.2024.107714

[81] S. Peng, Y. Yang, W. Li, S. Lin, S. Chu, T. Xiong, J. Ge, L. Sheng, J. Wang, H. Xu. Discovery of Novel PI3K/BRD4 Dual Inhibitors for Esophageal Cancer: Rational Design, Optimization, and Senescence-Inducing Mechanisms. Journal of Medicinal Chemistry 68 (2025) 23078-23102. https://doi.org/10.1021/acs.jmedchem.5c01920 DOI: https://doi.org/10.1021/acs.jmedchem.5c01920

[82] U.S. Food and Drug Administration. Withdrawn: Cancer Accelerated Approvals. (accessed October 2026).https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals

[83] U.S. Food and Drug Administration. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer, 10 October 2024. (accessed October 2026).https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive

[84] Celcuity Inc. FDA approval of REVTORPYK (gedatolisib) for HR-positive, HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer, 14 July 2026; approval based on the PIK3CA wild-type cohort of the randomized phase 3 VIKTORIA-1 trial (NCT05501886). https://ir.celcuity.com/news-releases/news-release-details/celcuity-announces-fda-approval-revtorpyktm-gedatolisib (accessed October 2026).

Downloads

Published

02-11-2026

Issue

Vol. 14 (2026)

Section

Pharmacology

License

Copyright (c) 2026 Jayshree Jangir, Prachi Patel, Drashti Shah, Ashish Shah, Vashisth Bhavsar, Ashish Patel

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Phosphoinositide 3-kinase-based dual-target inhibitors for cancer therapy: rational design, structure-activity relationships and biological evaluation: Review paper. (2026). ADMET and DMPK, 14, Article 3693. https://doi.org/10.5599/admet.3693

Most read articles by the same author(s)